VANDETANIB

IUPAC name:

N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy]quinazolin-4-amine

CAS No.

443913-73-3

Molecular Weight:

475.4 g.mol−1

Molecular Formula:

C22H24BrFN4O2

Granule:

Available - Ready to press

Mechanism Of Action:

Vandetanib is a selective and potent inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (RE-arranged during Transfection) tyrosine kinases.

EGFR- and VEGFR-dependent signaling are both clinically validated pathways in cancer, including non-small-cell lung cancer. RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer led to orphan-drug designation by the regulatory authorities in the USA and EU.

Indication:

It indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Use in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks.

information

Category: Oncology

January 21, 2024

Desloratadine

Anti-Histamine

Cas No: 100643-71-8

Mechanism Of Action: Desloratadine is a non-sedating, long-acting antihistamine that selectively blocks peripheral histamine H1-receptors. It is the major active metabolite of loratadine and works

Voriconazole

Anti-Microbial

Cas No: 137234-62-9

Mechanism Of Action: Voriconazole is a triazole antifungal agent that works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase1. This enzyme is crucial for

Enoxaparin Sodium

Cardiovascular

Cas No: 679809-58-6

Mechanism Of Action: Enoxaparin, a low molecular weight heparin (LMWH), works primarily by activating antithrombin III, which in turn inhibits factor Xa and IIa (thrombin).

Tirzapatide

Anti-Diabetic

Cas No: 2023788-19-2

Mechanism Of Action : Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This means it mimics the

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1